EUVIMEDScopri EUVIMED
BeobachtungsstudieOpen access

Semaglutide and Tirzepatide in a Remote Weight Management Program: 12-Month Retrospective Observational Study

Rebecca Richards iD, William Lunt iD, Michael Whitman iD, Giulia Spaltro iD, Rachel Hall iD

JMIR Formative Research · 2025

DOI: 10.2196/81912 ↗

At a glance

Beobachtungsstudie in JMIR Formative Research, 2025. Written by Rebecca Richards and 4 co-authors. Institution: Second Nature, London, United Kingdom. Major MEDLINE topics: Glucagon-Like Peptides, Tirzepatide, Obesity, Weight Reduction Programs. Cited 10 times so far (Crossref); 48 references. The full text is freely available in PubMed Central.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Background

Obesity affects >890 million adults worldwide, and traditional lifestyle interventions often lack long-term success. While glucagonlike peptide-1 receptor agonists (GLP-1RAs) have shown strong weight loss outcomes, access to specialist care is limited by cost and capacity.

Objective

This study evaluated the effectiveness, feasibility, acceptability, and potential cost-effectiveness of a 12-month remote GLP-1RA–supported weight management program, comparing outcomes between tirzepatide and semaglutide.

Methods

This retrospective analysis included 339 participants (n=278, 82% women) who completed a 12-month remote weight management program using either tirzepatide (n=209, 61.7%) or semaglutide (n=130, 38.3%) between February and June 2024. The program combined medication, app-based behavioral support, coaching from registered dietitians and nutritionists, and clinical oversight. It featured 5 phases with evidence-based behavior change techniques, monthly monitoring, and safety protocols. Primary outcomes were mean weight change and proportions achieving ≥10% and ≥15% weight loss. Secondary outcomes included behavior changes, side effects, acceptability, feasibility, and estimated cost-effectiveness compared to National Health Service care.

Results

Mean weight change at 12 months was −22.9 kg (–22.1% of baseline weight, SD 8%; P

Subjects

MeSH terms (MEDLINE)

Glucagon-Like PeptidesTirzepatideObesityWeight Reduction ProgramsHumansFemaleMaleRetrospective StudiesMiddle AgedAdultCost-Benefit AnalysisWeight LossTreatment OutcomeFeasibility StudiesGlucagon-Like Peptide 1Semaglutide

Author keywords

GLP-1RAbehavioral interventiondigital healthglucagonlike peptide-1 receptor agonistobesityremote health care deliverysemaglutidetelemedicineweight lossweight management

Substances

Glucagon-Like PeptidesTirzepatideGlucagon-Like Peptide 1Semaglutide

Authors and institutions

  • Second Nature, London, United Kingdom.

ORCID profiles: Rebecca Richards, William Lunt, Michael Whitman, Giulia Spaltro, Rachel Hall

Cite

APA

Richards, R., Lunt, W., Whitman, M., Spaltro, G., & Hall, R. (2025). Semaglutide and Tirzepatide in a Remote Weight Management Program: 12-Month Retrospective Observational Study. JMIR Formative Research. https://doi.org/10.2196/81912

Vancouver

Richards R, Lunt W, Whitman M, Spaltro G, Hall R. Semaglutide and Tirzepatide in a Remote Weight Management Program: 12-Month Retrospective Observational Study. JMIR Formative Research. 2025. doi:10.2196/81912

BibTeX
@article{Richards2025,
  author = {Richards, Rebecca and Lunt, William and Whitman, Michael and Spaltro, Giulia and Hall, Rachel},
  title = {Semaglutide and Tirzepatide in a Remote Weight Management Program: 12-Month Retrospective Observational Study},
  journal = {JMIR Formative Research},
  year = {2025},
  doi = {10.2196/81912}
}
Start for free →